Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab for intestinal inflammation and mucosal healing in active axial spondyloarthritis
2009-018085-35Phase 4Completed
- Sponsor
- Regionshospitalet Silkeborg
- Start
- May 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adalimumab in ankylosing spondylitis (AS) and axial spondyloarthritis (axSpA), sponsored by Regionshospitalet Silkeborg. Primary endpoint: Mucosal healing after 20 weeks assessed by capsule endoscopy. Started May 2010; status: completed.
02
Drugs
03
Conditions
ankylosing spondylitis (AS)axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on 2009-018085-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-018085-35.